GoodRx Holdings, Inc. (GDRX)

NMS – Real vaqt narxi. Valyuta: USD

3.63

-0.17 (-4.48%)

Bozor ochiq: Aug 12, 2026, 2:12 PM EDT

3.75

-0.05 (-1.32%)

Oldingi bozordan keyin: Aug 11, 2026, 7:41 PM EDT

12.08.2026

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.

07.08.2026

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.'

06.08.2026

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

06.08.2026

GoodRx Q2 Earnings Call Highlights

GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.

06.08.2026

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.

06.08.2026

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

06.08.2026

GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Videolar

07.08.2026

Positive

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

Press-relizlar

05.08.2026

GoodRx Reports Second Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026. Second Quarter 2026 Highlights Revenue of $200.4 million Net income of $8.5 million; Net income margin of 4.3% Adjusted Net Income1 of $26.8 million; Adjusted Net Income Margin1 of 13.4% Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 3.

GoodRx Holdings, Inc. (GDRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GoodRx Holdings, Inc. (GDRX)

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership